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AbstrACt
Introduction There is increasing evidence demonstrating 
the benefits of exercise in counteracting cancer treatment- 
related fatigue. Immunotherapy is an established 
treatment for advanced melanoma, and is associated 
with fatigue in a third of patients. The safety and 
efficacy of exercise in counteracting treatment- related 
fatigue in patients with advanced melanoma receiving 
immunotherapy are yet to be determined. This study aims 
to assess the safety, adherence to and acceptability of a 
mixed- methods parallel- group, pilot randomised controlled 
trial of a personalised, 12- week semi- supervised exercise 
programme prescribed by an exercise physiologist (iMove) 
in 30 patients with stage IV melanoma scheduled to 
commence immunotherapy: single agent ipilimumab, 
nivolumab or pembrolizumab, or combination ipilimumab 
and nivolumab. The trial will be used to provide preliminary 
evidence of the potential efficacy of exercise for managing 
fatigue.
Methods and analysis Thirty participants will be 
recruited from a specialist cancer centre between May 
and September, 2019. Participants will be randomised 1:1 
to receive iMove, or usual care (an information booklet 
about exercise for people with cancer). Feasibility data 
comprise: eligibility; recruitment and retention rates; 
adherence to and acceptability of exercise consultations, 
personalised exercise programme and study measures; 
and exercise- related adverse events. Patient- reported 
outcome measures assess potential impact of the exercise 
intervention on: fatigue, role functioning, symptoms and 
quality of life. Follow- up will comprise five time points over 
24 weeks. Physical assessments measure physical fitness 
and functioning.
Ethics and dissemination This study was reviewed 
and approved by the Peter MacCallum Cancer Centre 
Human Research Ethics Committee (HREC/48927/PMCC-
2019). The findings from this trial will be disseminated 
via conference presentations and publications in peer- 
reviewed journals, and by engagement with clinicians, 
media, government and consumers. In particular, we will 
promote the outcomes of this work among the oncology 
community should this pilot indicate benefit for patients.
trial registration number ACTRN12619000952145; 
Pre- results.
IntroduCtIon
WHO estimated approximately 62 000 people 
died from melanoma in 2015 globally1. In 
Australia, there were 1,190 deaths from 
melanoma in 2019.2 Until recently, survival 
rates for those diagnosed with advanced 
melanoma were low, however the intro-
duction of immune checkpoint inhibitors 
that target programmed cell death protein 
1 and cytotoxic T- lymphocyte- associated 
protein 4 ligands, commonly referred to as 
‘immunotherapy’, has resulted in significant 
long- term survival gains for a proportion of 
these people.3–6 Immunotherapy can cause a 
variety of side effects which can impact quality 
of life, the most common being fatigue.7 
Immunotherapy- related fatigue occurs in a 
third of patients8 and has been reported by 
strength and limitations of this study
 ► This trial will provide novel data regarding the feasi-
bility of delivering exercise interventions to counter-
act immunotherapy- related fatigue in the advanced 
melanoma population.
 ► Given the success of immunotherapy as a treat-
ment for melanoma, and many other cancers, de-
veloping an exercise intervention which counteracts 
immunotherapy- related fatigue has the potential to 
benefit many patients.
 ► Exercise physiologists undertaking physical assess-
ments cannot be blinded to participation randomis-
ation outcomes due to pragmatic design limitations.
 ► This is a single site study, so may not produce re-
sults that are directly relevant to all patients and all 
settings; well- designed multi- site trials are needed 
for this purpose.
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patients as having a detrimental effect on their ability to 
engage in many facets of their lives, particularly caring for 
children and working.9
Cancer- related fatigue is a well- known side effect of 
anti- cancer therapies. Exercise interventions have been 
developed to prevent or counteract fatigue with prom-
ising results.10 11 Research into the impact of strength 
and resistance- based exercise on cancer and treatment- 
related symptoms has been undertaken in breast, pros-
tate and colorectal cancer populations, during or after 
chemotherapy or radiotherapy.10 11 The Clinical Oncology 
Society of Australia recently issued a position statement 
on exercise for cancer patients, that recommends weekly 
participation in both aerobic and resistance training 
activities.12 Importantly, the statement in combination 
with current research supports that generic prescrip-
tion of exercise therapy is safe, tolerable and efficacious 
for improving symptoms experienced by patients with 
cancer, both during and after anti- cancer therapy.11 13 
However, few empirical evaluations of the role of exercise 
in combating symptoms of the cancer or side effects of 
treatment have included patients either with melanoma 
or those receiving immunotherapy. A feasibility study 
in patients with stage IV melanoma where exercise was 
prescribed as part of a broader supportive care interven-
tion, indicated exercise was acceptable and achievable for 
patients receiving single agent immunotherapy.14
Given the rapid expansion of immunotherapy into main-
stream treatment of melanoma, and increasingly other 
cancers, exercise interventions which effectively reduce 
immunotherapy- related fatigue have the potential to 
benefit many patients. The iMove programme, a 12- week 
personalised exercise physiologist (EP)- prescribed exer-
cise programme, has therefore been developed for 
patients diagnosed with advanced melanoma receiving 
immunotherapy. The primary aims of this pilot trial are 
to assess the: (i) safety and acceptability of the iMove 
programme to patients, and (ii) feasibility of conducting 
a definitive randomised controlled trial (RCT). Second, 
the trial will provide preliminary evidence of efficacy of 
an exercise intervention to combat fatigue, as well as 
other measures of interest.
MEthods
trial design and setting
The trial is a mixed- methods parallel- group, randomised 
controlled pilot trial. Qualitative and quantitative 
methods will be used. This study will be run at a specialist 
cancer hospital in Melbourne, Australia.
Patient and public involvement
The i- Move pilot trial is the product of consumer- driven 
research. Melanoma Patients Australia recently sought 
advice from our group about the potential for exercise to 
ameliorate immunotherapy- induced fatigue, as patients 
and families had been asking for advice, and for research 
to be conducted in the area. Our project steering 
committee comprises a consumer advocate to advise on 
project design, operations and materials, specifically to 
assess the burden of the intervention and participation 
requirements.
Participants
Patients diagnosed with stage IV melanoma scheduled 
to receive, or recently commenced, combination or 
single agent immunotherapy (ipilimumab, nivolumab, 
pembrolizumab) will be invited to participate. Specific 
eligibility criteria include: aged 18 years or older, Eastern 
Cooperative Oncology Group (ECOG) performance 
status of 0–2, not yet received second infusion of immu-
notherapy, able to speak and read English sufficiently to 
complete questionnaires and take part in the exercise 
programme without use of interpreter, deemed suitable 
to take part in an exercise intervention by their treating 
clinician (i.e. no medical contraindications to exercise), 
and have access to a smartphone.
Exclusion criteria comprises the following contrain-
dications to safe exercise: grade ≥3 peripheral neurop-
athy, a recent history (within the previous 3 months) of 
myocardial infarction or unstable angina, cerebrovascular 
event or transient ischaemic attack or pulmonary embolic 
event, or existing acute or chronic deep vein thrombosis, 
or active sepsis.
All interested eligible patients will be requested to 
provide written informed consent.
Physical and safety assessment
Consented patients will complete a general health and 
medical safety assessment with an EP to determine trial 
eligibility (as detailed earlier). Data generated from the 
safety assessment will also be used to identify any comor-
bidities or other health considerations which will need to 
be factored into exercise prescription for the interven-
tion group.
Once eligibility is confirmed, the EP will complete a base-
line physical assessment using standard clinical exercise 
tests measuring cardiovascular fitness, upper limb strength 
and lower limb strength (see table 1 for further informa-
tion on assessments). Outcomes will be used by the EP to 
develop a personalised exercise programme for partici-
pants randomised to the intervention group. The EP will 
also determine whether the participant meets the Clinical 
Oncology Society of Australia guidelines for activity in 
people with cancer12:
 ► At least 150 min of moderate intensity or 75 min 
of vigorous- intensity aerobic exercise (eg, walking, 
jogging, cycling, swimming) each week; and
 ► Two to three resistance exercise (ie, lifting weights) 
sessions each week involving moderate to vigorous- 
intensity exercises targeting the major muscle 
groups.
Participants will be stratified at randomisation 
according to whether they meet these guidelines or not.
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Table 1 Participant data collection will occur at five time points throughout the trial
Participant activity and data collection
Weeks
≤Second 
infusion
1 2 3 4 5 6 7 8 9 10 11 12 13 17 25
i i i i i i i
T0 T1 T2 T3 T4 T5
Trial consent x
Patient- reported outcome measures 
(both groups)
                                
Fatigue: FACIT F, brief fatigue inventory x x x x x
Role functioning: PROMIS ability to 
participate in social roles and activities 6a
x x x x x
Symptoms: Edmonton Symptom 
Assessment Scale
x x x x x
Quality of life: SF-36 x x x x x
Adherence and crossover: Godin Leisure- 
time Exercise Questionnaire
x x x x x
Safety assessment (both groups)                                 
Peripheral neuropathy and other health 
comorbidities
x
Physical assessments (both groups)                                 
30 s chair sit to stand test x x x
6 min walk test x x x
The AKPS x x x
Peripheral neuropathy x
Comorbidities/musculoskeletal morbidities x
Intervention                                 
Personalised intervention programme 
provided
x
Face- to- face personalised exercise 
consultations
x x x x x
Telephone personalised exercise 
consultations
x x x x
Active control                                 
Cancer council exercise for people living 
with cancer booklet provided
x
EP consultation x
Feasibility measures                                 
Project operations (accrual, adherence, 
retention)
x x x x x x x x x x x x x x x x
Qualitative intervention patient interview 
(adherence, acceptability)
x
Exercise- related adverse event log (safety) x x x x x x x x x
EP data collection instrument (adherence) x x x x x x x x x x
Qualitative EP Interview (acceptability, 
adherence, fidelity)
                          x     
*x indicates event is scheduled to occur
AKPS, Australia- modified Karnofsky Performance Scale; EP, exercise physiologist; FACIT- F, Functional assessment of chronic illness 
therapy- fatigue; SF-36, Short Form 36 Health Survey Questionnaire.
randomisation and allocation concealment
Participants will be randomised 1:1 to either the interven-
tion or control group. The research team will perform 
randomisation and notification of randomisation 
outcome to both patients and the EP. Randomisation will 
be performed using a computer- generated block alloca-
tion sequence (block size of 6), stratified by current exer-
cise activity: whether meeting Clinical Oncology Society 
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Figure 1 iMove study flow chart.
of Australia guidelines for activity in people with cancer. 
Allocation will be concealed from participants until after 
they have completed baseline physical and safety assess-
ment and baseline patient- reported outcome measures . 
For those randomised to the intervention group, the EP 
will commence development and prescription of their 
exercise programme (see figure 1).
sample size
The target sample is 30 participants randomised, 15 per 
group. The target sample is pragmatic, based on available 
funds and trial time frames; however, stepped rules of thumb 
for pilot sample sizes were considered.15 16 If 30 patients are 
accrued in 3 months, then the expected monthly accrual 
rate is 10 patients per month with an exact 95% CI of 6.75 to 
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14.3 patients per month, corresponding to a 95% CI for the 
accrual rate over 3 months of 20.2 to 42.8 patients. Power 
will be insufficient to detect minimum clinically important 
differences between trial arms on patient- reported outcomes 
measures; however, if the 95% CIs for trial arm comparisons 
at follow- ups T3 through T5 (see table 1) contain important 
differences, the intervention will be viewed as promising.15
Intervention
The intervention will be delivered by an accredited EP 
based in the health service. Each individual programme 
will be designed by the EP, accounting for relevant demo-
graphic and clinical characteristics (eg, disease, age), 
physical suitability, any safety considerations and current 
exercise activities including work, home and leisure. 
The EP will use the Physitrack smartphone application 
(app) to provide each participant with their exercise 
programme. Physitrack is free for patients to download 
to their smartphone. Participants are instructed to use 
the app to view and log exercise activities completed, but 
not change the prescribed exercise programme. EP guid-
ance provided as part of the exercise intervention will 
comprise:
 ► Four face- to- face sessions at the hospital: once every 
3 weeks (or every 2–4 weeks for those receiving 
nivolumab) coinciding with immunotherapy infusion 
appointments.
 ► Four telephone supervision sessions scheduled for the 
week after the face- to- face session.
 ► One final face- to- face session at the conclusion of 
the exercise intervention to discuss ongoing physical 
activity and community resources patients can access 
close to home.
Each participant will be prescribed an individualised 
exercise programme which includes moderate inten-
sity aerobic exercise, resistance training exercises and 
stretching of the major muscle groups. The most common 
forms of exercise which will be prescribed will be walking 
and cycling. As per the American College of Sports Medi-
cine and Exercise and Sports Science Australia guidelines 
the aim is for aerobic exercise to be undertaken 3–5 times 
per week (20–45 min duration) with resistance training 
performed 2–3 times per week.17 18 Clinical reasoning will 
be used during the follow- up appointments to adjust the 
exercise intensity depending on treatment symptoms and 
side effects experienced by the participant.
Aerobic training heart rate range goal will be between 
50% and 80% of predicated heart rate max and rating 
of perceived exertion on Borg’s scale, with participants 
asked to maintain intensity between 12 and 15 (out of 20) 
throughout the session. Strength training will consist of 5–7 
upper and lower limb exercises of the major muscle groups, 
starting at two sets of 10 repetitions. Strength training exer-
cises incorporate body weight exercises, dumbbells and 
barbells. Initial progression of the programme involves 
increasing the number of repetitions per set from 10 to 12 
to 15, then increasing sets from 2 to 3. Following increase in 
sets, weight is added for further resistance
During both telephone and face- to- face sessions, the EP 
will monitor safety and exercise progress, and update the 
exercise prescription if required.
Control
Participants randomised to receive the active control will 
be provided with a copy of the Cancer Council New South 
Wales booklet ‘Exercise for people living with cancer’ 
which provides general information on exercise for 
people with cancer.19 After 24 weeks, participants in the 
control group will receive a face- to- face session with the 
EP to provide information about accessing community- 
based exercise supports via their general practitioner.
outcomes
Study outcomes were designed to determine whether a 
multi- site efficacy RCT is feasible. Table 2 details each 
outcome, objective, data collection method and where 
relevant, pre- specified feasibility criteria.
data collection and management
Data pertaining to each study outcome will be collected 
and recorded usingfour main methods: project operations 
database, custom EP data collection instrument, patient- 
reported outcome measures, and qualitative interviews. 
Data relating to iMove impact (patient- reported outcome 
measures and physical assessment) will be collected across 
five time points, outlined in detail in table 1.
The project operations database is designed to collect 
data as per Consolidated Standards of Reporting Trials 
(CONSORT) guidelines20 and feasibility outcomes, namely 
recruitment and ineligibility. The EP- log is a custom- built 
workbook designed for the EPs to record safety and phys-
ical assessment outcomes, and to document prescribed 
exercise programme activities, consultation (face- to- face 
and telephone) discussions, exercise- related adverse events 
and adherence and acceptability data. Additional feasibility 
outcome data regarding acceptability and adherence will 
be collected via participant and EP qualitative interviews at 
the conclusion of trial participation.
Physical assessment data will be collected and recorded 
in the EP data collection instrument using the 30 s chair 
stand test21; the 6 min walk test22; the arm curl test23 and 
the Australia- modified Karnofsky Performance Scale.24
Semi- structured interviews will be undertaken by 
the research assistant 1:1 with the EP and participant 
randomised to the intervention group. The interview will 
comprise questions on the EP experience and perspec-
tives regarding the feasibility and acceptability of the 
intervention, barriers and facilitators to adherence to 
the exercise programme in particular immunotherapy- 
related fatigue and what could be improved if the inter-
vention was part of a larger RCT.
Patient- reported outcome measures will be emailed 
to participants to complete using the REDCap data 
management programme,25 and will comprise: the func-
tional assessment of chronic illness therapy; brief fatigue 
inventory, Patient- Reported Outcomes Measurement 
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Table 2 Outcomes, data collection method and feasibility criteria
Outcome Objective Data collection Feasibility criteria
Feasibility
Accrual
  Estimate the recruitment rate and 
appraise reasons for ineligibility
Project operation database On average, we will recruit 10 
participants per month for 3 months
Adherence
  Investigate adherence to iMove face- to- 
face EP consultations
Recorded by EP At least 75% of participants 
randomised to iMove will attend at 
least three of the first four face- to- 
face consultations
  Investigate adherence to iMove 
telephone EP consultations
Recorded by EP At least 75% of participants 
randomised to iMove will attend at 
least three of the first four telephone 
consultations
  Investigate adherence to a 
personalised, prescribed exercise 
intervention.
Recorded by EP; Participant 
qualitative interview, Physitrack
N/a
Acceptability
  Investigate the acceptability of the EP 
consultation sessions.
Participant and EP qualitative 
interview
N/a
  Investigate the acceptability of a 
personalised, prescribed exercise 
intervention
Recorded by EP; Participant and EP 
qualitative interview
N/a
  Assess the acceptability and 
appropriateness of study measures
Participant qualitative interview N/a
Retention
  Assess the retention of participants at 
16 weeks
Recorded by EP At least 70% of participants will 
complete their physical assessment 
at T3
  Assess the retention of participants at 
16–24 weeks
PROMs completion At least 70% of participants will 
complete their patient- reported 
outcome measures assessments at 
T3 through T5
Safety
  Determine the number and type of 
exercise- related adverse events
Recorded by EP N/a
Impact
  Investigate the potential impact of 
iMove on fatigue and other patient- 
reported outcomes
Patient- reported outcome measures:
 ► FACIT- F
 ► BFI
 ► PROMIS ability to participate in 
aocial roles and activities—SF 6a
 ► SF-36
 ► ESAS
 ► GLTPAQ
N/a
  Investigate the potential impact of 
iMove on objective measures of fitness
Physical assessment:
 ► 30 s chair stand test
 ► 6 min walk test
 ► Arm curl test
N/a
BFI, Brief fatigue inventory; EP, exercise physiologist; ESAS, Edmonton Symptom Assessment Scale; FACIT- F, Functional assessment 
of chronic illness therapy- fatigue; GLTPAQ, Godin Leisure- time Physical Activity Questionnaire; PROMs, patient- reported outcome 
measures; SF-36, Short Form 36 Health Survey Questionnaire; SF, Short Form.
Information System (PROMIS) V.2.0—ability to partic-
ipate in social roles and activities 6a; Short Form 36 
Health Survey Questionnaire; the revised Edmonton 
Symptom Assessment Scale; the Godin Leisure- time 
Physical Activity Questionnaire (see table 3 for more 
information).
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data analysis plan
Feasibility outcomes
The main feasibility outcomes are recruitment and reten-
tion. The main acceptability outcome is adherence to 
the iMove consultation sessions. Recruitment data will be 
summarised using a rate and 95% CI using the Poisson 
distribution.7 Adherence and retention data will be 
summarised using a proportion and 95% CI; the latter 
will be estimated using the Wilson method.26 The main 
feasibility outcomes will be judged against prespecified 
criteria (table 2). Time spent by the EPs completing 
intervention- related activity will be recorded in the EP 
data collection instrument, including total time spent 
per patient and activity- specific time such as intervention 
preparation. Means and SD will be used to summarise time 
data. Counts and percentages will be used to summarise 
data on exercise- related adverse events.
Counts and percentages will be used to summarise data 
on missing items and forms or tests for patient- reported 
outcome measures and objective measures of fitness, respec-
tively. Patient- reported outcome measures will be scored 
according to author guidelines. Means, SD and ranges will 
be used to summarise scores for patient- reported outcome 
measures and objective measures of fitness at each time 
point by trial arm. Analysis will include all available data. 
Values for missing forms (or measures) will not be imputed.
Analysis of patient- reported outcome measures data 
and objective measures of fitness will be carried out by 
fitting a linear mixed model to each outcome separately. 
Models will include fixed effects for trial arm, time and a 
trial arm- by- time interaction, as well as a random partic-
ipant effect. Baseline assessment will be included as a 
covariate. Differences between trial arms at post- baseline 
assessments will be calculated from these models.27
Qualitative data
Data recorded by EPs (described in table 1) will be analysed 
using content analysis methodology. Content analysis allows 
for exploration of phenomenon such as motivation, expe-
riences and views of participants in order to answer clini-
cally relevant health questions.28 Data will be classified into 
codes, categories and (where relevant) themes using an 
iterative process. At the conclusion of analysis, findings will 
be presented and discussed with members of the project 
team. Discrepancies will be discussed and resolved until 
consensus with the coding framework is reached.
Interviews with EP’s and patients will be audio- recorded, 
transcribed and analysed using interpretive description 
methodology.29 Interpretive description was selected for 
analysis as it is useful for exploring experiential data as it 
allows for deeper and richer thematic exploration of the 
data rather than sorting and summing common statements, 
and provides practical outcomes for clinical health services 
improvement.29
data management
Demographic, questionnaire and clinical data will be 
recorded on hard- copy forms, and then entered into a 
database built and stored on the hospital REDCap platform. 
Only key project personnel including the research assistant, 
data manager, principal investigator and project manager 
will have access to hard- copy and electronic data, in accor-
dance with the National Statement on Ethical Conduct in 
Human Research 2007 (updated 2018) and the Australian 
Code for Responsible Conduct of Research 2018. During 
the data collection period, regular quality assurance will be 
undertaken to ensure accuracy, precision and completeness 
of trial data. At the conclusion of data collection, export 
and analysis, the project will be archived on the REDCap 
platform with backups stored as password- protected files on 
hospital secure servers, and hard- copy forms will be placed 
in secure storage. Five years after publication or dissemina-
tion of project outcomes, hard- copy and electronic data will 
be destroyed.
dissemination
The findings from this trial will be disseminated via normal 
academic channels such as conference presentations and 
publications in peer- reviewed journals but also by engage-
ment with clinicians, media, government and consumers. 
In particular, we will seek to promote the outcomes of this 
work among the broader oncology community around the 
benefits of exercise for patients receiving immunotherapy. 
Results from this work will also be fed back to consumers 
via our partner patient advocacy groups, and via trial partic-
ipants. Appropriate publications will be identified and 
planned by the project steering committee but will include 
a publication of the protocol design, results based on the 
main protocol using the trial group name, and subsequent 
publications of data subsets only if appropriate.
dIsCussIon
This feasibility study will provide preliminary data on the 
safety of exercise in people with melanoma on immuno-
therapy. This data will provide practitioners reassurance 
they can supervise exercise to mediate cancer- related 
fatigue in this population, provided an initial assessment is 
first undertaken, and the exercise prescription tailored to 
the individual participant. It will also provide some indica-
tion of the likely effect of exercise on a range of physical 
and psycho- social endpoints.
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